58,673 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC acquired a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 58,673 shares of the biotechnology company’s stock, valued at approximately $587,000.

Several other large investors also recently made changes to their positions in BCRX. Larson Financial Group LLC grew its position in shares of BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,267 shares during the period. Allworth Financial LP acquired a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at approximately $52,000. Focus Partners Wealth acquired a new position in BioCryst Pharmaceuticals in the 3rd quarter valued at $77,000. Envestnet Portfolio Solutions Inc. bought a new position in BioCryst Pharmaceuticals during the fourth quarter worth about $81,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $81,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on BCRX shares. Wedbush dropped their price target on BioCryst Pharmaceuticals from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Citizens Jmp boosted their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 7th. Royal Bank Of Canada decreased their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.60.

BioCryst Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ:BCRX opened at $9.82 on Friday. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.22. The firm has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.55 and a beta of 0.55. The stock’s 50 day moving average is $9.71 and its 200-day moving average is $9.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. During the same period last year, the company earned $0.15 earnings per share. The business’s revenue was up 33.6% on a year-over-year basis. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.